Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria

Performance standards for antimicrobial susceptibility testing

Mary Jane Ferraro · 2001 · 9.8K citations

Life Sciences, Infectious Diseases, Microbiology +11

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti, Roger Echols, Yuko Matsunaga et al. · The Lancet Infectious Diseases · 2020 · 792 citations

Life Sciences, Infectious Diseases, Microbiology +14

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink, Yuko Matsunaga, Mari Ariyasu et al. · The Lancet Infectious Diseases · 2020 · 464 citations

Pharmacy, Clinical Sciences, Infectious Diseases +17

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth, David van Veenhuyzen, Roger Echols et al. · The Lancet Infectious Diseases · 2018 · 404 citations

Life Sciences, Infectious Diseases, Microbiology +10

Modified Carbapenem Inactivation Method for Phenotypic Detection of Carbapenemase Production among Enterobacteriaceae

Virginia Pierce, Patricia J. Simner, David Lonsway et al. · Journal of Clinical Microbiology · 2017 · 396 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17